<DOC>
	<DOCNO>NCT00003601</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use tretinoin and/or fenretinide may effective way prevent recurrence development dysplastic nevus syndrome . PURPOSE : Randomized phase II trial compare effectiveness tretinoin without fenretinide treat patient dysplastic nevus syndrome .</brief_summary>
	<brief_title>Tretinoin With Without Fenretinide Treating Patients With Dysplastic Nevus Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy ( clinical histologic evidence regression ) topical tretinoin without systemic fenretinide patient dysplastic nevi personal family history cutaneous melanoma . OUTLINE : This randomize , double-blind study . Patients stratify accord personal history cutaneous melanoma v family history cutaneous melanoma least 2 blood relative . Patients randomize one two treatment arm . Arm I : Patients receive topical tretinoin twice daily oral fenretinide day 6 month . Tretinoin apply one half back untreated side back serve match control . Arm II : Patients receive topical tretinoin arm I twice daily oral placebo day 6 month . Treatment continue arm absence disease progression unacceptable toxicity . Patients follow 6 month . PROJECTED ACCRUAL : There 38 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dysplastic Nevus Syndrome</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinically dysplastic nevi personal history cutaneous melanoma and/or family history cutaneous melanoma two blood relative ( blood relative include first , second , third degree relative blood line ) Clinically dysplastic nevus define : At least 4 mm diameter flatness ( either component throughout ) least 1 follow : Variable pigmentation Irregular asymmetrical outline Indistinct border Must least 10 large ( diameter least 4 mm ) clinically dysplastic nevus trunk extremity ( exclude head , pubic area , breast woman , hand , and/or knee ) No stage III IV melanoma Patients history melanoma receive adjuvant therapy must 1 year completion therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL AST le 2 time normal Alkaline phosphatase less 2 time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No symptomatic arteriosclerotic coronary artery disease No history coronary artery disease Other : Fasting triglyceride level le 210 mg/dL Fasting cholesterol level le 350 mg/dL No nonmalignant disease would preclude administration retinoids No psychiatric condition would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : No prior coronary bypass surgery Other : No prior systemic retinoids No concurrent vitamin ( except daily multivitamin ) dietary supplement No concurrent systemic therapy hyperlipidemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>melanoma</keyword>
</DOC>